CompletedPhase 2NCT00516295
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Studying Extraskeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Patrick Leavey, MDChildren's Oncology Group
- Intervention
- topotecan hydrochloride(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 1-29 years · All sexes
- Timeline
- 2008 – 2010
Study locations (1)
- Children's Oncology Group, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00516295 on ClinicalTrials.gov